11711 North Meridian Street
About Assembly Biosciences
Assembly Biosciences, Inc. is a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome. The HBV program is focused on advancing a new class of potent, oral core inhibitors that have the potential to increase cure rates for chronically infected patients. The microbiome program is developing novel oral live microbial biotherapeutic candidates with Assembly’s fully integrated platform, including a robust process for strain identification and selection, GMP banking and production, and targeted delivery to the lower gastrointestinal tract with the GEMICEL® technology. For more information, visit assemblybio.com.
Stock Exchange: NASDAQ
Stock Symbol: ASMB
R & D Main Facility:
331 Oyster Point Blvd.
South San Francisco, CA 94080
24 articles with Assembly Biosciences
Safety and Antiviral Activity of Assembly Biosciences’ First and Second Generation Core Inhibitor Candidates In the Treatment of Chronic Hepatitis B to be Featured in a Late Breaking Session at AASLD
Phase 2a studies of ABI-H0731 + nucleos(t)ide analogs (Nrtl) in HBeAg+ patients show faster and deeper declines in HBV DNA and RNA with combination than Nrtl alone, as well as subsequent declines in the surrogate markers of cccDNA with long-term treatment
8/9/2019Biopharma companies strengthen their senior leadership teams and boards of directors.
New Year, fresh start? Could be. WalletHub recently compared more than 180 cities across the U.S., using 30 key indicators to evaluate their job strength. Some of those factors were job opportunities, employment growth, monthly average starting salary and employment outlook.
Assembly Biosciences, Inc. today announced that the company will have an oral presentation of the full data set from the Phase 1b study of ABI-H0731 at the upcoming American Association for the Study of Liver Diseases (AASLD) Annual Meeting (The Liver Meeting®), being held November 9-13 in San Francisco.
Assembly Biosciences Selects Next-Generation CpAM Candidate For Advancement Into Clinical Development
Assembly Biosciences Announces The Closing And Early Termination Of Hart-Scott-Rodino Waiting Period For License Of Microbiome Gastrointestinal Development Programs To Allergan
Assembly Biosciences Announces Successful Completion Of ABI-H0731 Phase Ia Trial And Upcoming Conference Presentations
Allergan Enters Into Licensing Agreement With Assembly Biosciences To Obtain Worldwide Rights To Microbiome Gastrointestinal Development Programs
Assembly Biosciences Initiates Phase I Clinical Program Of ABI-H0731 For Treatment Of Chronic Hepatitis B Virus Infection
Assembly Biosciences To Present Data At The International Liver Congress 2016 That Supports Advancing Its CpAM Candidates Into HBV Clinical Trials
Assembly Biosciences To Present Data On New Series Of HBV Core Protein Allosteric Modifiers At The International Liver Congress™ 2016
Clinical Study Shows Assembly Biosciences' Oral Gemicel Technology Can Achieve Targeted Delivery To The Lower GI Tract For Microbiome And Other Applications
Assembly Biosciences To Describe Improved Methods For HBV Drug Development At Major International Meeting
Assembly Biosciences Discusses Mechanism Of Action Of Its HBV Antiviral Program At 2nd ANRS HBV Cure Workshop